{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:38:03Z","timestamp":1768423083820,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s10067-019-04557-7","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T22:02:42Z","timestamp":1556056962000},"page":"2001-2009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Rituximab in connective tissue disease\u2013associated interstitial lung disease"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-2425","authenticated-orcid":false,"given":"Ana Catarina","family":"Duarte","sequence":"first","affiliation":[]},{"given":"Ana","family":"Cordeiro","sequence":"additional","affiliation":[]},{"given":"Bruno Miguel","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Bernardes","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Martins","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Cordeiro","sequence":"additional","affiliation":[]},{"given":"T\u00e2nia","family":"Santiago","sequence":"additional","affiliation":[]},{"given":"Maria In\u00eas","family":"Seixas","sequence":"additional","affiliation":[]},{"given":"Ana Roxo","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"4557_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3097","volume":"12","author":"FV Castelino","year":"2010","unstructured":"Castelino FV, Varga J (2010) Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 12:213. \n                    https:\/\/doi.org\/10.1186\/ar3097","journal-title":"Arthritis Res Ther"},{"key":"4557_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.autrev.2013.05.001","volume":"12","author":"B Marigliano","year":"2013","unstructured":"Marigliano B, Soriano A, Margiotta D et al (2013) Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 12:1076\u20131084. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2013.05.001","journal-title":"Autoimmun Rev"},{"key":"4557_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/0885066613516579","volume":"30","author":"JJ Solomon","year":"2015","unstructured":"Solomon JJ, Fischer A (2015) Connective tissue disease-associated interstitial lung disease: a focused review. J Intensive Care Med 30:392\u2013400. \n                    https:\/\/doi.org\/10.1177\/0885066613516579","journal-title":"J Intensive Care Med"},{"key":"4557_CR4","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ 352:h6819. \n                    https:\/\/doi.org\/10.1136\/bmj.h6819","journal-title":"BMJ"},{"key":"4557_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/RTI.0b013e3181c1acec","volume":"24","author":"DA Lynch","year":"2009","unstructured":"Lynch DA (2009) Lung disease related to collagen vascular disease. J Thorac Imaging 24:299\u2013309. \n                    https:\/\/doi.org\/10.1097\/RTI.0b013e3181c1acec","journal-title":"J Thorac Imaging"},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666. \n                    https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"4557_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G, for the Scleroderma Lung Study Research Group (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026\u20131034. \n                    https:\/\/doi.org\/10.1164\/rccm.200702-326OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4557_CR8","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970. \n                    https:\/\/doi.org\/10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"key":"4557_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"4557_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","volume":"121","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Lee C, Valenzi E, Witt LJ, Adegunsoye A, Hsu S, Chen L, Montner S, Chung JH, Noth I, Vij R, Strek ME (2016) Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med 121:117\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.rmed.2016.11.007","journal-title":"Respir Med"},{"key":"4557_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","volume":"34","author":"Y Ge","year":"2015","unstructured":"Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, Wang G (2015) The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review. Clin Rheumatol 34:2097\u20132103. \n                    https:\/\/doi.org\/10.1007\/s10067-015-3065-0","journal-title":"Clin Rheumatol"},{"key":"4557_CR12","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437\u20132444. \n                    https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","journal-title":"Arthritis Rheum"},{"key":"4557_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1183\/09031936.00092309","volume":"35","author":"EJ Kim","year":"2010","unstructured":"Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, van Uden JH, Lee JS, King TE, Collard HR (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35:1322\u20131328. \n                    https:\/\/doi.org\/10.1183\/09031936.00092309","journal-title":"Eur Respir J"},{"key":"4557_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"4557_CR15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yal\u00e7\u0131nda\u011f N, Jayne DR, Mukhtyar C (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583\u20131594. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"},{"key":"4557_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirol Carlton Vic 19:353\u2013359. \n                    https:\/\/doi.org\/10.1111\/resp.12214","journal-title":"Respirol Carlton Vic"},{"key":"4557_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00163911","volume":"40","author":"GJ Keir","year":"2012","unstructured":"Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA (2012) Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 40:641\u2013648. \n                    https:\/\/doi.org\/10.1183\/09031936.00163911","journal-title":"Eur Respir J"},{"key":"4557_CR18","first-page":"215","volume":"32","author":"DB Fitzgerald","year":"2015","unstructured":"Fitzgerald DB, Moloney F, Twomey M et al (2015) Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 32:215\u2013221","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"key":"4557_CR19","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","volume":"55","author":"C Sharp","year":"2016","unstructured":"Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, Millar AB, Gunawardena H (2016) Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatol Oxf Engl 55:1318\u20131324. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew195","journal-title":"Rheumatol Oxf Engl"},{"key":"4557_CR20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","volume":"183","author":"RM Bois du","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C et al (2011) Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183:1231\u20131237. \n                    https:\/\/doi.org\/10.1164\/rccm.201007-1179OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4557_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/13993003.00357-2015","volume":"47","author":"JJ Solomon","year":"2016","unstructured":"Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ (2016) Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47:588\u2013596. \n                    https:\/\/doi.org\/10.1183\/13993003.00357-2015","journal-title":"Eur Respir J"},{"key":"4557_CR22","doi-asserted-by":"publisher","first-page":"i86","DOI":"10.1093\/rheumatology\/kev088.092","volume":"54","author":"AR Kabia","year":"2015","unstructured":"Kabia AR, Yusof M, Yuzaiful M et al (2015) 092. Efficacy and safety of rituximab in rheumatoid arthritis patients with concomitant interstitial lung disease: 10-year experience at single centre. Rheumatology 54:i86\u2013i86. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev088.092","journal-title":"Rheumatology"},{"key":"4557_CR23","doi-asserted-by":"publisher","first-page":"272303","DOI":"10.1155\/2012\/272303","volume":"2012","author":"W Hartung","year":"2012","unstructured":"Hartung W, Maier J, Pfeifer M, Fleck M (2012) Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Rep Immunol 2012:272303. \n                    https:\/\/doi.org\/10.1155\/2012\/272303","journal-title":"Case Rep Immunol"},{"key":"4557_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4236\/ojra.2012.23011","volume":"02","author":"EL Matteson","year":"2012","unstructured":"Matteson EL, Bongartz T, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF (2012) Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis 02:53\u201358. \n                    https:\/\/doi.org\/10.4236\/ojra.2012.23011","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"4557_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","volume":"47","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47:552\u2013553. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kem357","journal-title":"Rheumatology"},{"key":"4557_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.semarthrit.2009.09.003","volume":"40","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP (2010) Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 40:127\u2013136. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2009.09.003","journal-title":"Semin Arthritis Rheum"},{"key":"4557_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatol Oxf Engl 49:271\u2013280. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kep093","journal-title":"Rheumatol Oxf Engl"},{"key":"4557_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JHW, Maurer B, Huscher D, van Laar J, Allanore Y, Distler O, EUSTAR Rituximab study group (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"key":"4557_CR29","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1136\/thoraxjnl-2014-206260.14","volume":"69","author":"C Sharp","year":"2014","unstructured":"Sharp C, Dodds N, Edey A, Adamali H, Gunawardena H, Millar A (2014) S8 rituximab therapy for refractory myositis related interstitial lung disease unresponsive to conventional immunosuppression: the Bristol interstitial lung disease service experience. Thorax 69:A7\u2013A7. \n                    https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206260.14","journal-title":"Thorax"},{"key":"4557_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aal\u00f8kken TM, G\u00fcnther A, Walle-Hansen R, Garen T, Molberg \u00d8 (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatol Oxf Engl 54:1420\u20131428. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev004","journal-title":"Rheumatol Oxf Engl"},{"key":"4557_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 66:351\u2013357. \n                    https:\/\/doi.org\/10.1136\/ard.2006.057919","journal-title":"Ann Rheum Dis"},{"key":"4557_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203308094653","volume":"18","author":"JA Reynolds","year":"2009","unstructured":"Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18:67\u201373. \n                    https:\/\/doi.org\/10.1177\/0961203308094653","journal-title":"Lupus"},{"key":"4557_CR33","doi-asserted-by":"publisher","unstructured":"Druce KL, Iqbal K, Watson KD, et al (2017) Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open 3. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2017-000473","DOI":"10.1136\/rmdopen-2017-000473"},{"key":"4557_CR34","doi-asserted-by":"publisher","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","volume":"4","author":"T Nakashita","year":"2014","unstructured":"Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S (2014) Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 4:e005615. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2014-005615","journal-title":"BMJ Open"},{"key":"4557_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","volume":"30","author":"M Schiff","year":"2010","unstructured":"Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613\u2013624. \n                    https:\/\/doi.org\/10.2165\/11537460-000000000-00000","journal-title":"Clin Drug Investig"},{"key":"4557_CR36","doi-asserted-by":"publisher","unstructured":"Suarez-Almazor ME, Belseck E, Shea B et al (2000) Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev CD001157. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001157","DOI":"10.1002\/14651858.CD001157"},{"key":"4557_CR37","doi-asserted-by":"publisher","unstructured":"Suarez-Almazor ME, Spooner C, Belseck E (2000) Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev CD001461. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001461","DOI":"10.1002\/14651858.CD001461"},{"key":"4557_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09059180.00008014","volume":"24","author":"M Shaw","year":"2015","unstructured":"Shaw M, Collins BF, Ho LA, Raghu G (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24:1\u201316. \n                    https:\/\/doi.org\/10.1183\/09059180.00008014","journal-title":"Eur Respir Rev"},{"key":"4557_CR39","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/rheumatology\/ker267","volume":"50","author":"J-F Boitiaux","year":"2011","unstructured":"Boitiaux J-F, Debray M-P, Nicaise-Roland P, Adle-Biassette H, Danel C, Clerici C, Aubier M, Mariette X, Cadranel J, Crestani B (2011) Idiopathic interstitial lung disease with anti-SSA antibody. Rheumatol Oxf Engl 50:2245\u20132250. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ker267","journal-title":"Rheumatol Oxf Engl"},{"key":"4557_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","volume":"10","author":"P Ghillani","year":"2011","unstructured":"Ghillani P, Andr\u00e9 C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 10:509\u2013513. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2011.03.004","journal-title":"Autoimmun Rev"},{"key":"4557_CR41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatol Oxf Engl 49:1713\u20131719. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keq149","journal-title":"Rheumatol Oxf Engl"},{"key":"4557_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol 36:352\u2013359. \n                    https:\/\/doi.org\/10.1080\/08830185.2017.1346092","journal-title":"Int Rev Immunol"},{"key":"4557_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","volume":"27","author":"I Fleury","year":"2016","unstructured":"Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MHJ, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C (2016) Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 27:390\u2013397. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv616","journal-title":"Ann Oncol"},{"key":"4557_CR44","doi-asserted-by":"publisher","unstructured":"Enomoto Y, Inui N, Yoshimura K et al (2016) Lung cancer development in patients with connective tissue disease\u2013related interstitial lung disease. Medicine (Baltimore) 95. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000005716","DOI":"10.1097\/MD.0000000000005716"},{"key":"4557_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.21037\/jtd.2017.12.134","volume":"10","author":"S Watanabe","year":"2018","unstructured":"Watanabe S, Saeki K, Waseda Y et al (2018) Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. J Thorac Dis 10:799\u2013807","journal-title":"J Thorac Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04557-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T23:24:04Z","timestamp":1587511444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04557-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04557-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"9 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted according to the principles of the Declaration of Helsinki (revised in Fortaleza \u2013 2013) and after approval from the Ethics Committee of Hospital Garcia de Orta.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}